학술논문
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Document Type
Academic Journal
Author
Source
Cancer Cell International. July 15, 2015, Vol. 15
Subject
Language
English
Abstract
Author(s): Khalid O Alfarouk[sup.1] , Christian-Martin Stock[sup.2] , Sophie Taylor[sup.3] , Megan Walsh[sup.3] , Abdel Khalig Muddathir[sup.4] , Daniel Verduzco[sup.5] , Adil H H Bashir[sup.1] , Osama Y Mohammed[sup.6] , [...]
Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer. Keywords: Drug, Resistance, Pharmacokinetics, ADME, pH, MDR
Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer. Keywords: Drug, Resistance, Pharmacokinetics, ADME, pH, MDR